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Purpose: Galactokinase (GALK1) deficiency is a rare hereditary
galactose metabolism disorder. Beyond cataract, the phenotypic
spectrum is questionable. Data from affected patients included in
the Galactosemias Network registry were collected to better
characterize the phenotype.
Methods: Observational study collecting medical data of 53 not
previously reported GALK1 deficient patients from 17 centers in 11
countries from December 2014 to April 2020.
Results: Neonatal or childhood cataract was reported in 15 and 4
patients respectively. The occurrence of neonatal hypoglycemia and
infection were comparable with the general population, whereas
bleeding diathesis (8.1% versus 2.17–5.9%) and encephalopathy
(3.9% versus 0.3%) were reported more often. Elevated transami-
nases were seen in 25.5%. Cognitive delay was reported in 5
patients. Urinary galactitol was elevated in all patients at diagnosis;
five showed unexpected Gal-1-P increase. Most patients showed
enzyme activities ≤1%. Eleven different genotypes were described,
including six unpublished variants. The majority was homozygous
for NM_000154.1:c.82C>A (p.Pro28Thr). Thirty-five patients
were diagnosed following newborn screening, which was clearly
beneficial.
Conclusion: The phenotype of GALK1 deficiency may include
neonatal elevation of transaminases, bleeding diathesis, and
encephalopathy in addition to cataract. Potential complications
beyond the neonatal period are not systematically surveyed and a
better delineation is needed.
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INTRODUCTION
Hereditary galactosemias are a group of disorders caused by
genetic defects in galactose metabolism. Galactosemia type
II (OMIM 230200), also known as galactokinase (GALK1;
EC 2.7.1.6) deficiency, has a worldwide incidence of
1:1,000,000,1 although it can be higher in regions with a
founder effect. However, since many newborn screening
(NBS) programs do not detect GALK1 deficiency, this
incidence is probably an underestimation. The first
description dates back to 1933 when Fanconi2 described a
patient with cataract associated with milk ingestion, a
condition he termed galactose diabetes. It was in 1965 that
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Gitzelmann3 discovered that this patient suffered from
GALK1 deficiency.8
Two galactokinase-like genes can be distinguished. GALK1
(OMIM *604313), located on chromosome 17q24, encodes
galactokinase and is involved in galactose metabolism. GALK2
(OMIM *137028), located on chromosome 15q21.1-q21.2,
encodes N-acetylgalactosamine kinase (EC 2.7.1.157) and is
not primarily involved in galactose metabolism.4 Galactoki-
nase is part of the GHMP superfamily of structurally similar
proteins, which comprises mostly small molecule kinase
enzymes. The abbreviation GHMP refers to the involved
kinases: galactokinase, homoserine kinase, mevalonate kinase,
and phosphomevalonate kinase.5 Kinetically, human galacto-
kinase follows an ordered ternary complex mechanism, with
adenosine triphosphate (ATP) binding first. The human
enzyme is intolerant to many single amino acid substitutions.
This is important in the molecular pathology of GALK1
deficiency.6,7 Variants in the GALK1 gene are associated with
GALK1 deficiency and, at present, the mutational spectrum
comprises more than 30 variants. The most frequent disease-
causing variants are the founder variant NM_000154.1:
c.82C>A (p.Pro28Thr), common in the Roma population,
and the Osaka variant NM_000154.1:c.593C>T (p.Ala198-
Val), common in the Japanese and Korean populations.6
In human metabolism, galactose is essential for the
galactosylation of complex molecules. In addition to the
dietary source, there is endogenous production that mainly
occurs from the turnover of glycoconjugates.8 Galactose is
mainly processed through the Leloir pathway, in which the
first enzyme GALK1 catalyzes the conversion of α-D-
galactose to α-D-galactose-1-phosphate (Gal-1-P) at the
expense of ATP. In erythrocytes of healthy controls the
range of the GALK1 activity measured by liquid chromato-
graphy tandem mass spectrometry (LC-MS/MS assays) is
1.0–2.7 μmol·(g Hgb)−1·hr−1, with a mean GALK1 activity
of 1.8 ± 0.43 μmol·(g Hgb)−1·hr−1.9
GALK1 deficient patients are biochemically characterized
by hypergalactosemia and elevated values of galactitol and
galactonic acid resulting from the activation of the reductive
and oxidative pathways of galactose disposal. In GALK1
deficient patients these galactitol levels can rise to 2500
mmol/mol creatinine prior to diet therapy. After introduc-
tion of the diet, the urinary galactitol values significantly
decrease.10,11
Bilateral cataract, characterized by central lens opacities
with the appearance of an oil droplet, seems to be the only
consistent manifestation in patients with GALK1 deficiency.
Accumulation of galactitol, due to the conversion of excess
galactose by aldose reductase, is responsible for the develop-
ment of cataracts.12 In the presence of hypergalactosemia,
high amounts of galactose are transported to the lens cells.
Aldose reductase is abundantly present in the epithelial cells,
located at the anterior side of the lens.13 Subsequently, high
levels of galactose are reduced to galactitol, creating an
osmotic phenomenon with lens swelling, lysis, and sugar
cataracts as the result.14 Using their mouse model, Ai et al.12
showed the link between the development of cataract and the
level of aldose reductase in lens cells. GALK1 knockout mice
did not develop cataract when fed a galactose diet due to
absent expression of aldose reductase in the lens cells.
However, after introduction of the human aldose reductase
transgene, these knockout mice developed cataract within the
first day of life.12 In humans, cataracts can be resolved by
dietary restriction of galactose if the diet is initiated before the
second month of life. If the diet is not timely instituted and
vision impairment has already occurred, surgical intervention
is needed.15
In addition to cataracts, neonatal complications such as
hepatosplenomegaly, hypoglycemia, and failure to thrive
have been reported. Pseudotumor cerebri has also been
described and its development is related to the accumula-
tion of galactitol in the brain cells with subsequent cerebral
edema as result.16 Other manifestations, such as intellectual
disability and developmental delay, have been reported.10,17
It is arguable whether other manifestations are the result of
GALK1 deficiency or related to other genetic, epigenetic, or
environmental factors. However, these findings have raised
questions about the true phenotypic spectrum of this entity.
In an effort to gather more data internationally and survey
the occurrence of other symptoms in addition to cataract,
the GalNet registry data were used. This registry was created
in 2014 by the members of the Galactosemia Network
(GalNet, www.galactosemianetwork.org).18 In this study,
we present the data of 53 previously unpublished patients
from different countries, aiming to characterize the
phenotypic spectrum and the diagnosis, treatment, and
follow-up of this entity.
MATERIALS AND METHODS
Ethics statement
The international network for the galactosemias (GalNet),
established in 2012, has developed an online registry (https://
ecrf.ctcm.nl/macro/) that includes patients with the different
galactosemias from several countries as described in Rubio-
Gozalbo et al.19 It was established in accordance with Good
Clinical Practice and following General Data Protection
Regulation. The local ethics committee of the coordinating
center (Maastricht University Medical Center) approved the
study (application number METC 13–4–121.6/ab), which was
subsequently approved by participating partners. All patients or
their authorized representatives gave written consent.
Inclusion and exclusion criteria
Between December 2014 and April 2020, data of patients with
established GALK1 deficiency were collected. In total, 53
patients were included. GALK1 deficiency was defined as
GALK1 enzyme activity below 20% of reference value and/or
GALK1 disease-causing variants.
Predicted structural effects on GALK1 enzyme
Changes in protein stability of unpublished variants were
estimated in silico using PredictSNP.20
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Statistical analysis
Data for analysis were exported from the original database in
MACRO to SPSS. Medians and ranges for continuous
variables and percentages for categorical variables were
calculated with descriptive analyses. All clinical outcomes
were classified as absent or present to calculate the
associations between clinical outcomes and variables using
Fisher’s exact test; p values less than 0.05 were considered
statistically significant. For some variables, p values with odds
ratios (OR) and 95% confidence intervals (CI) are described.
Because of the high amount of missing data, the valid number,
defined as the number of available data per variable, was used
for expressing the statistical findings in percentages. These
missing data were a consequence of the retrospective nature
of data collection or due to the young age of patients, which
hampered evaluation of long-term follow-up. The results of
the statistical analyses may be biased, when >10% of the data
were missing.21
RESULTS
Patients’ characteristics
A total of 53 patients, not previously reported in the literature,
and originating from 11 countries and 17 different centers,
were included in this study (Table 1). The gender was not
equally distributed (64.2% male and 35.8% female), with a
median age of 10.4 years (range: 1–35). Most patients were
Caucasian. In total, 35 patients were diagnosed following NBS
(Table S1). Although more patients with GALK1 deficiency
are known at several centers, they could not be included due
to loss of follow-up (Table 1).
Phenotypic spectrum
Cataract
Fifteen of the reported 53 patients (28.3%) showed cataract in
the neonatal period; in 1 patient it was not clear whether the
cataract was present neonatally. Neonatal cataract that
persisted throughout childhood was reported in 11 of these
15 patients and in 7 of them surgical removal was performed.
In the other patients, neonatal cataract resolved with dietary
restrictions. The occurrence of neonatal cataract was sig-
nificantly lower in patients with initiation of diet within the
first two months of life (p < 0.001) and was less frequently
reported in patients diagnosed by NBS (p < 0.001). New
lenticular changes in childhood were reported in 4 patients
and in 3 of them surgical removal of the cataract was
performed because of impaired vision (Table S1, Fig. 1).
Neonatal illness
In the registry, acute neonatal illness was defined as having one
of the following symptoms or findings: elevated transaminases
(alanine aminotransferase [ALT] or aspartate aminotransferase
[AST] > 30U/L), bleeding diathesis (abnormal prothrombin
time [PT] and/or activated partial thromboplastin time
[APTT]), encephalopathy (depressed consciousness with or
without neurological signs), clinical signs of infection, and/or
hypoglycemia (glucose < 2.6 mmol/L). The different parameters
were not reported in all 53 patients. The given numbers refer to
the patients in which the specific parameter was assessed. The
most common sign in the neonatal period was the elevated
transaminases in 12 of the 47 (25.5%) patients. In addition, 3 of
the reported 37 (8.1%) showed bleeding diathesis, 2 of the
reported 51 (3.9%) patients showed encephalopathy, 1 of the
reported 50 (2.0%) patients showed signs of infection, and 2 of
the reported 47 (4.3%) showed hypoglycemia (Table S1).
Neurological and cognitive complications
Developmental delay was assessed in 47 patients, of whom
3 suffered from cognitive developmental delay, 2 suffered from
motor developmental delay, and 2 from developmental delay
on both domains. Of these 7 patients in whom developmental
Table 1 Participating countries and centers.
Country Center Number of
patients
Countries and centers with number of included GALK1 deficient patients
Austria Medizinische Universität Wien, Vienna 6
Universitätsklink für Pädiatrie, Tirol
Kliniken GmbH, Innsbruck
3
University Children’s Hospital, Parcelsus
Medical University, Salzburg
1
Belgium University Hospital Ghent 1
University Hospital Leuven 2
Queen Fabiola Children’s University
Hospital
2
France Hôpital Antoine Béclère, Clamart 1
Germany Clinic for Pediatric Kidney, Liver and
Metabolic Diseasesa
15
Greece Agia Sofia Children’s Hospitala 1
Ireland National Centre for Inherited Metabolic
Disorders
1
Netherlands Amsterdam Medical Center 2
Portugal Hospital Santa Maria Lisboa 3
Spain Complejo Hospitalario Universitario de
Santiago
5
Hospital Sant Joan de Déu 5
Switzerland Inselspital, University Hospital, Bern 1
USA Boston Children’s Hospital 1
Children’s Hospital of Philadelphiaa 3
Total 53
Country and center(s) with GALK1 deficient patients not included
in article
Croatia Klinički bolnički centar Zagreb 2
Ireland Temple Street Children’s University
Hospital
1
Netherlands Erasmus Medical Center Rotterdam 1
Maastricht University Medical Center 1
University Medical Center Groningen 1
Spain Hospital Clinic de Barcelona 1
Total 7
aCenter to be included in GalNet Registry.
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delay was reported, three suffered from acute neonatal illness.
In 4 patients with developmental delay, cataract was reported.
Three of the 4 patients with cataract developed the cataract in
the neonatal period; the other was reported with lenticular
changes during childhood (Table S1). No significant associa-
tion was found between the occurrence of cataract and the
presence of developmental delay. The occurrence of develop-
mental delay was less frequently reported in patients diagnosed
following NBS (p= 0.029, but not significant after Bonferroni).
Language delay was present in 3 of the 34 patients (8.8%) in
whom language delay was assessed. Three of the reported
40 patients (7.5%) suffered from speech disorders. In addition,
other symptoms such as movement disorders including
tremor, dystonia, ataxia, and general motor abnormalities;
microcephaly; and psychiatric disorders such as attention
deficit–hyperactivity disorder and anxiety disorder were
reported in some patients (Table S1).
Female gonads
In 8 of 19 female patients, gonadal follow-up was reported.
One of them showed delayed puberty and 7 of the 8 patients
had a spontaneous puberty. No primary ovarian insufficiency
was reported (Table S1).
Bone health
Vitamin D levels, calcium intake, physical activity, and
fractures were included in the electronic case report form
(eCRF). In 13 patients the vitamin D levels were assessed.
Vitamin D levels between 50 and 75 nmol/L were defined as
insufficient and levels below 50 nmol/L were defined as
deficient. Vitamin D deficiency was reported in 9 patients,
vitamin D insufficiency in 2 patients, and normal vitamin D
levels were seen in 2 patients. Among the 45 patients in whom
the usage of supplements was reported, 1 patient only used
calcium supplements, 15 patients only used vitamin D
supplements, and 11 patients used both calcium and vitamin
D supplements.
Recommended physical activity was defined according to
the World Health Organization (WHO) as 60 minutes of
moderate to vigorous intensity physical activity per day for
children and 150 minutes per week for adults. The physical
activity was assessed in 20 patients; it was sufficient in 14 and
insufficient in 6. Bone fractures were not reported in any of
the 23 patients.
Metabolites
Data on urinary galactitol concentrations were available in 18
patients, with the most recent galactitol values reported in 13
patients. Ten of these 13 patients showed elevated levels
(Table S1). In 23 patients, information about total galactose in
blood at diagnosis was available and showed an increased
total galactose. Surprisingly, increased Gal-1-P values during
the neonatal period were reported in 5 patients, returning to
normal beyond the neonatal period. In patients 4, 18, and 41
!
Characteristics of GALK1 deficient patients
Number of patients
Diagnosed by NBS 4/15
Start of diet Before second month of life 5/15
Beyond second month of life 9/15
No diet 1/15
Genetic variation c.[82C>A];[82C>A] 5/15
(NM_000154.1) c.[136G>A];[766C>T] 1/15
c.[766C>T];[1055C>A] 1/15
c.[388dupG];[388dupG] 1/15
c.[371G>A];[371G>A] 1/15
c.[520G>A];[510T>A] 1/15
Unknown 5/15
Characteristics of GALK1 deficient patients
Number of patients
Diagnosed by NBS 2/4
Start of diet Before second month of life 2/4
Beyond second month of life 2/4
Genetic variation c.[82C>A];[82C>A] 1/4
(NM_000154.1) c.[124G>A];[1036G>A] 1/4
Unknown 2/4
Cataract in neonatal period
n=15
Resolved with dietary restrictions
n=4
Persisted throughout childhood
n=11
Cataract formation throughout childhood
n=4
Surgical removal of cataract
n=3
Surgical removal of cataract
n=7
Fig. 1 Cataract formation in study population. A total of 15 patients were reported with cataract in the neonatal period. Characteristics of the patients
with neonatal cataract are shown in the figure above. In 4 patients, cataract resolved after initiation of dietary restrictions. In the other 11 patients, the
cataract persisted through childhood and in 7 patients surgical removal was performed. Cataract formation throughout childhood was reported in 4
patients; surgical removal was performed in 3. NBS newborn screening.
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the Gal-1-P values were 14.0, 13.8, and 24.2 mg/dL respec-
tively (reference: <10.0 mg/dL) and in patients 14 and 15
they were 0.20 and 0.30 µmol/g Hb respectively (reference:
<0.05 µmol/g Hb) (Table S1).
Enzymatic measurements and genotype
In 29 patients the GALK1 gene (NM_000154.1) variant was
reported. The genotypic spectrum revealed that 17 of 26
patients were homozygous for the most common variant
NM_000154.1:c.82C>A (p.Pro28Thr). In 44 patients the
enzyme activity was described: <1% in 27 patients, between
1% and 5% in 14 patients, and >10% in 3 patients (11.6%,
16.1%, and 18.0%). No statistically significant associations were
found with enzyme activities <1% or ≥1% and clinical outcomes
neonatal cataract (p= 0.082; OR 0.176 [0.029–1.051]), any sign
of acute neonatal illness (p= 0.480; OR 2.074 [0.463–9.291])
and motor or mental or both developmental delay (p= 0.668;
OR 0.619 [0.108–3.539]).
The most common genotype NM_000154.1:c.[82C>A];
[82C>A] was associated with an enzyme activity between
0% and 3%. The genetic variants NM_000154.1:c.[1144C>T];
[1144C>T] and NM_000154.1:c.[149G>T];[149G>T] were
reported with enzyme activities of 0% and between 0% and
0.4%, respectively (Table S1).
Six unpublished variants were reported, namely
NM_000154.1:c.136G>A (p.Asp46Asn), NM_000154.1:
c.1055C>A (p.Thr352Lys), NM_000154.1:c.700del (p.Ser234A-
lafs*30), NM_000154.1:c.[(?_945-7)_(*64_?)del], NM_000154.1:
c.388dupG (p.Val130Gly*73), and NM_000154.1:c.510T>A
(p.Cys170Ter). These unpublished variants are all rated likely
pathogenic when following the criteria of the American
College of Medical Genetics and Genomics (ACMG). They
are all absent from the Genome Aggregation Database
(gnomAD; https://gnomad.broadinstitute.org/) in homozy-
gous state, all affect highly conserved regions of the GALK1
gene, and are predicted to affect function by MutationTaster.
Two of the novel genetic variants result in amino acid changes
in GALK1, namely p.Asp46Asn and p.Thr352Lys (Fig. 2a).
Asp46 forms part of the active site of human GALK1 where it
binds galactose through C3-OH and C4-OH (Fig. 2b).
5
Previous work has shown that alteration of Asp46 to alanine
results in soluble, but catalytically inactive, GALK1.22 In silico
prediction using PredictSNP suggested that this unpublished
change in residue 46, aspartic acid to asparagine, is
destabilizing (87% expected accuracy). This, combined with
likely weaker binding to galactose, explains the loss of activity
observed in patients. Thr352 forms part of a ß-sheet structure
that has previously been implicated in controlling the
specificity and activity of GALK1.23 However, no experi-
mental studies on this residue have been reported. PredictSNP
suggests that this change, threonine to lysine, is also
destabilizing (87% expected accuracy). The effects of the
deletions are harder to predict. Most likely, they either result
in truncated, misfolded, inactive protein, or no protein at all
due to nonsense mediated (messenger RNA [mRNA]) decay.
Diet
In total, 39 patients initiated the galactose-restricted diet
within the first two months of life, 12 patients beyond the
second month of life, and 1 patient did not follow a diet. Data
on 1 patient are missing. Thirty-five patients in whom diet
was initiated within the second month of age were diagnosed
following NBS (p < 0.001).
In total, 50 patients followed a galactose-restricted diet.
Among these 50 patients, 12 of them were also restricted from
nondairy galactose sources, defined as a strict diet.
DISCUSSION
Cataract is the constant finding in GALK1 deficiency.
Other symptoms in addition to cataract were reported in
the described population.
Phenotypic spectrum
In this study population, 19 of 53 patients showed cataract
formation. Six of them were diagnosed with NBS and in 7
patients the diet was introduced before the second month of
a b
Fig. 2 The location of the two new disease-associated point variants in the human GALK1 structure. (a) The three-dimensional structure of
human GALK1 is shown in green. Adenosine triphosphate (ATP) (cyan) and galactose (hot pink) are shown bound in the active site. The two affected
residues are shown: Asp46 (orange) and Thr352 (yellow). (b) A close-up of the active site showing how Asp46 binds, and helps orientate, the galactose
molecule through C3-OH and C4-OH. The structure is based on PDB: 1WUU with gaps filled, selenomethionines converted to methionines, and AMP; PNP
to ATP.5,40 Images created with PyMol.
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life (Fig. 1). Despite the introduction of a galactose-restricted
diet, 4 patients developed cataract throughout childhood. This
could be explained by poor diet compliance, since a galactose-
restricted diet is important in preventing the development or
progression of cataract. In the study population, hypoglyce-
mia was reported in 4.3% and the presence of infection was
reported in 2.0%, both comparable with the general popula-
tion (5–15% and 4% respectively24,25). The occurrence of
bleeding diathesis and encephalopathy in our study popula-
tion were 8.1% and 3.9% respectively, thus higher than in the
general population (2.17–5.9% and 0.3% respectively26,27).
The data of this study showed that in 7 of the 47 patients
(14.9%) with follow-up, cognitive, and/or motor develop-
mental delay was reported. Vitrikas et al.28 described that the
general prevalence of cognitive developmental delay was
1–1.5%. This information was derived from children receiving
services in the United States and had been established through
multiple tests (Ages and Stages Questionnaire, the Language
Development Survey, and the MacArthur-Bates Communi-
cative Development Inventory). Regarding the data of our
study population, 5 of the 47 patients (10.6%) were reported
to have mental developmental delays. This information was
based on the positive answer by the treating physician to the
question in the registry, cognitive developmental delay,
present or absent. No data on testing were reported. However,
2 of the 5 patients followed regular education, one followed
special education while siblings followed regular education.
In the other 2 patients the type of education was unknown
(Table S1). Nevertheless, a difference of 10% between the
GALK1 deficient patients and the general population
warrants further investigation based on uniform guidelines
with comparable instruments to assess the presence of
cognitive developmental delay in GALK1 deficient patients.
Timson et al. described a correlation between the
phenotypic spectrum of GALK1 deficiency and the biochem-
ical consequences of specific variants. Hereby, the GALK1
phenotype was divided in three subtypes: severe, defined as
the development of cataract in the newborn period;
intermediate, defined as developing cataract during child-
hood; and mild, defined as increased cataract risk in middle
age.29 Genetic variants leading to protein variants related to
the severe phenotype were associated with misfolding of the
GALK1 protein, since those variants produced insoluble
proteins on recombinant expression in Escherichia coli (E.
coli). Homozygosity for NM_000154.1:c.82C>A (p.Pro28Thr)
was the most reported genotype in the study population, and
this variant falls within the spectrum of a severe phenotype.
On the other hand, genetic variants associated with
intermediate phenotype produced soluble proteins in E. coli
and showed altered kinetic aspects. A reduced turnover
number was noticed in the variant NM_000154.1:c.1036G>A
(p.Gly346Ser).29 Genetic variants associated with the mild
phenotype are likely a genetic factor for age-related cataracts,
such as the Osaka variant.30
Different variants might also lead to deficiency in different
tissues. In GALK1 deficiency the occurrence of a Philadelphia
variant has been described. Individuals with this variant are
typically asymptomatic and show normal GALK1 activity in
leukocytes and reduced GALK1 activity in erythrocytes.31
A similar phenomenon is known in classic galactosemia
wherein the missense GALT variant NM_000155.3:c.404C>T
(p.Ser135Leu) results in absent GALT activity in erythrocytes
and 10% residual activity in other tissues as liver and
leukocytes.32 In this GALT variant long-term complications
are uncommon.
Other genetic, epigenetic, or environmental factors may be
involved in the occurrence of other symptoms in addition to
cataract in GALK1 deficient patients. These findings strongly
encourage additional investigations in the future to unequi-
vocally link or exclude these other signs and symptoms to
GALK1 deficiency.
Metabolites
In general, metabolites are of enormous value for the diagnosis
and for monitoring the impact of the galactose-restricted diet in
galactosemias.
Hennermann et al.10 showed that initiation of diet resulted
in significant decrease of urinary galactitol, without normal-
ization of the values, in contrast to the galactose concentra-
tions in blood that normalize with initiation of diet. Regarding
our study population, normalization of urinary galactitol
occurred in 2 of 18 patients for whom galactitol values were
reported, indicating that urinary galactitol does not normalize
in the majority of the patients after start of the diet.
A surprising finding was the reported increase of Gal-1-P
value in 5 patients, returning to normal beyond the neonatal
period. Theoretically, the occurrence of an elevated Gal-1-P in
GALK1 deficiency seems to be unlikely. Pyhtila et al.33 also
described this finding in GALK1 deficient patients screened
with NBS, but related the elevated Gal-1-P to other causes
that influenced liver function or the circulation rather than
galactosemia. Total galactose assays were known for their
nonspecificity since they measure free galactose along with
galactose contributed from Gal-1-P through its reaction with
alkaline phosphatase. Tandem mass spectrometry (TMS) is
not capable of differentiating between different hexose
monophosphates (HMP) without the use of chromatographic
separation.34 Currently, more sensitive TMS with higher
specificity is used for galactosemia screening that measures
Gal-1-P instead of HMP with fewer false positive results.
Regarding the Gal-1-P values of the above 5 patients, it is
possible that these measured values were false positive due to
the measurement of other sugar phosphates rather than Gal-
1-P. In 3 patients, the method used to assess the Gal-1-P
concentration was not described. In 1 patient the colorimetric
method was employed and in the other patient, the two-step
fluorometric assay. In both tests, Gal-1-P is converted to
galactose. However, other sugar phosphates beside Gal-1-P
can be a substrate for alkaline phosphatase, which could then
lead to false positive results.35,36
Theoretically, patients with severe GALK1 deficiency on an
unrestricted diet might have massive elevations in plasma
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and tissue galactose leading to the formation of other
phosphorylated galactose compounds in hematopoietic cells
thus leading to a false positive result with methodology that
fails to exclusively measure Gal-1-P.
In addition to technical issues, other mechanisms might
be involved. Interestingly, Gal-1-P in the neonatal period
normalizing in the post neonatal period has also been
described in several galactose mutarotase (GALM) deficient
patients. GALM catalyzes the conversion of β-D-galactose to
α-D-galactose, which enters the Leloir pathway.37
Factors influencing clinical outcome
In several countries, screening for GALK1 deficiency is
implemented in the NBS program. The first GALK1 deficient
patient diagnosed following NBS was described by Thalham-
mer et al.38 Our study showed that patients diagnosed
following NBS had an early onset of a galactose-restricted diet
and decreased incidence of development of cataract.
The current treatment of GALK1 deficiency consists of a
lifelong galactose-restricted diet, which is recommended to
prevent lenticular changes or progression of cataract later in
life.15 In general, in case of severe progressed cataract, the lens
could be replaced by intraocular lens implantations fabricated
with polymethylmetacrylate (PMMA).13 After surgery, diet is
still recommended to prevent development of secondary
cataract. In addition, there is insufficient evidence that no
other symptoms are related to GALK1 deficiency.
Follow-up
The data from this study showed that in 7 of the 47 patients
with follow-up, developmental complications were reported.
Follow-up in gonadal and bone complications were missing in
the majority of the patients. Vitamin D levels assessed in only
13 patients, whose values indicated vitamin D deficiency,
which is a common global health problem and therefore not
necessarily related to the diet in GALK1 deficiency. Gonadal
follow-up was reported in only 8 female patients and
appeared normal.
The lack of follow-up in most patients exemplifies the need
for guidelines on diagnosis, treatment, and follow-up. Our
recommended clinical guideline for the management of
GALK1 deficient patients would include genetic and enzy-
matic measurements, as well as awareness of the occurrence of
neonatal complications. Periodic dietary, ophthalmological,
bone, gonadal (female), and brain follow-up would also be
included. The gonadal follow-up aims to identify primary
ovarian insufficiency. In the brain follow-up, developmental
and behavioral assessment, as well as neurological examina-
tion using validated measurements would be performed.
Evaluating bone health, including assessment of calcium and
vitamin D intake, physical activity, and DXA measurements
would be necessary. When patients develop symptoms other
than cataract, additional investigations are recommended to
exclude other genetic conditions related to these symptoms.
Deep phenotyping of patients with GALK1 deficiency may
improve our understanding and truly clarify the phenotypic
spectrum related to this entity.
Future treatments
Since aldose reductase plays a key role in the development of
sugar cataracts in GALK1 deficiency, aldose reductase
inhibitors could be considered as a potential therapeutic
strategy.39 The inhibition of aldose reductase prevents the
accumulation of galactitol as an osmotically significant polyol,
and theoretically could prevent cataracts and pseudotumor
cerebri in infancy. However, aldose reductase inhibitors may
not address other manifestations of the disease.
Treatments to restore GALK1 enzyme activity such as
pharmacological chaperones, GALK1 mRNA, and others
might also be possibilities in the future.
Study limitations
The study was limited by the low prevalence of this disease,
loss of follow-up in many patients, the retrospective nature
of data collection, as well as nonstandardized laboratory
methods and follow-up of patients in many countries.
Conclusion
We describe the phenotypic features of 53 patients with
GALK1 deficiency among whom six unpublished GALK1
variants were identified. The phenotypic spectrum of GALK1
deficiency can include neonatal elevation of transaminases,
bleeding diathesis, and encephalopathy in addition to cataract.
NBS with timely onset of the galactose-restricted diet was
beneficial for the development of cataract. A surprising
phenomenon was the reported elevation of Gal-1-P values,
which might be due to methodological factors (false positives)
or other hexokinase activities. Potential complications beyond
the neonatal period have not been systematically surveyed and
additional work-up to unequivocally link other sign and
symptoms to the GALK1 deficiency is missing, leaving the
impact of GALK1 deficiency questionable and indicating a
need to improve diagnosis, treatment, and follow-up of these
patients.
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